RenalytixAI: KidneyIntelX
Sep 18, 2020
RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients.
The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month.